ATE87946T1 - Polymer, seine herstellung und verwendung. - Google Patents

Polymer, seine herstellung und verwendung.

Info

Publication number
ATE87946T1
ATE87946T1 AT86303417T AT86303417T ATE87946T1 AT E87946 T1 ATE87946 T1 AT E87946T1 AT 86303417 T AT86303417 T AT 86303417T AT 86303417 T AT86303417 T AT 86303417T AT E87946 T1 ATE87946 T1 AT E87946T1
Authority
AT
Austria
Prior art keywords
high molecular
molecular polymer
compounds
polymer
production
Prior art date
Application number
AT86303417T
Other languages
English (en)
Inventor
Masaki Yamamoto
Hiroaki Okada
Yasuaki Ogawa
Tsutomu Miyagawa
Original Assignee
Takeda Chemical Industries Ltd
Wako Pure Chem Ind Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=14197161&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=ATE87946(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Takeda Chemical Industries Ltd, Wako Pure Chem Ind Ltd filed Critical Takeda Chemical Industries Ltd
Application granted granted Critical
Publication of ATE87946T1 publication Critical patent/ATE87946T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C08—ORGANIC MACROMOLECULAR COMPOUNDS; THEIR PREPARATION OR CHEMICAL WORKING-UP; COMPOSITIONS BASED THEREON
    • C08G—MACROMOLECULAR COMPOUNDS OBTAINED OTHERWISE THAN BY REACTIONS ONLY INVOLVING UNSATURATED CARBON-TO-CARBON BONDS
    • C08G63/00—Macromolecular compounds obtained by reactions forming a carboxylic ester link in the main chain of the macromolecule
    • C08G63/02—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds
    • C08G63/06—Polyesters derived from hydroxycarboxylic acids or from polycarboxylic acids and polyhydroxy compounds derived from hydroxycarboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
    • A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
    • A61K9/1605—Excipients; Inactive ingredients
    • A61K9/1629—Organic macromolecular compounds
    • A61K9/1641—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poloxamers
    • A61K9/1647—Polyesters, e.g. poly(lactide-co-glycolide)
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5005—Wall or coating material
    • A61K9/5021—Organic macromolecular compounds
    • A61K9/5031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, poly(lactide-co-glycolide)
    • B—PERFORMING OPERATIONS; TRANSPORTING
    • B01—PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01J—CHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J13/00—Colloid chemistry, e.g. the production of colloidal materials or their solutions, not otherwise provided for; Making microcapsules or microballoons
    • B01J13/02—Making microcapsules or microballoons
    • B01J13/06—Making microcapsules or microballoons by phase separation
    • B01J13/12—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution
    • B01J13/125—Making microcapsules or microballoons by phase separation removing solvent from the wall-forming material solution by evaporation of the solvent

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Polymers & Plastics (AREA)
  • Dispersion Chemistry (AREA)
  • Medicinal Preparation (AREA)
  • Polyesters Or Polycarbonates (AREA)
  • Addition Polymer Or Copolymer, Post-Treatments, Or Chemical Modifications (AREA)
  • Compositions Of Macromolecular Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Separation, Recovery Or Treatment Of Waste Materials Containing Plastics (AREA)
  • Processing Of Solid Wastes (AREA)
AT86303417T 1985-05-07 1986-05-06 Polymer, seine herstellung und verwendung. ATE87946T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
JP9761785 1985-05-07
EP86303417A EP0202065B1 (de) 1985-05-07 1986-05-06 Polymer, seine Herstellung und Verwendung

Publications (1)

Publication Number Publication Date
ATE87946T1 true ATE87946T1 (de) 1993-04-15

Family

ID=14197161

Family Applications (1)

Application Number Title Priority Date Filing Date
AT86303417T ATE87946T1 (de) 1985-05-07 1986-05-06 Polymer, seine herstellung und verwendung.

Country Status (8)

Country Link
US (2) US4728721A (de)
EP (1) EP0202065B1 (de)
JP (2) JP2551756B2 (de)
AT (1) ATE87946T1 (de)
CA (1) CA1262005A (de)
DE (1) DE3688213T2 (de)
HK (1) HK5796A (de)
HU (1) HU196703B (de)

Families Citing this family (162)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法
DE3641692A1 (de) * 1986-12-06 1988-06-09 Boehringer Ingelheim Kg Katalysatorfreie resorbierbare homopolymere und copolymere
US4897268A (en) * 1987-08-03 1990-01-30 Southern Research Institute Drug delivery system and method of making the same
JP2670680B2 (ja) * 1988-02-24 1997-10-29 株式会社ビーエムジー 生理活性物質含有ポリ乳酸系微小球およびその製造法
US6323307B1 (en) 1988-08-08 2001-11-27 Cargill Dow Polymers, Llc Degradation control of environmentally degradable disposable materials
US5424346A (en) * 1988-08-08 1995-06-13 Ecopol, Llc Biodegradable replacement of crystal polystyrene
US5180765A (en) * 1988-08-08 1993-01-19 Biopak Technology, Ltd. Biodegradable packaging thermoplastics from lactides
AU634723B2 (en) * 1988-08-08 1993-03-04 Biopak Technology, Ltd. Degradable thermoplastic from lactides
EP0428620B1 (de) * 1988-08-08 1999-03-03 Biopak Technology, Ltd. Verfahren zur Weichmachung von Lactidpolymerisaten
JP2714454B2 (ja) * 1988-11-07 1998-02-16 三井東圧化学株式会社 生体吸収性ポリエステルの製造方法
DE3936191C2 (de) * 1989-10-31 1996-10-17 Boehringer Ingelheim Kg Neue Copolymere aus Milchsäure und Weinsäure, ihre Herstellung sowie ihre Verwendung
MY107937A (en) * 1990-02-13 1996-06-29 Takeda Chemical Industries Ltd Prolonged release microcapsules.
JP2653255B2 (ja) * 1990-02-13 1997-09-17 武田薬品工業株式会社 長期徐放型マイクロカプセル
US5075115A (en) * 1990-04-02 1991-12-24 Fmc Corporation Process for polymerizing poly(lactic acid)
ATE168391T1 (de) * 1990-04-13 1998-08-15 Takeda Chemical Industries Ltd Biologisch abbaubare hochmolekulare polymere, ihre herstellung und ihre verwendung
MY108621A (en) * 1990-08-01 1996-10-31 Novartis Ag Polylactide preparation and purification
WO1992004413A1 (en) * 1990-09-06 1992-03-19 Biopak Technology Ltd Packaging thermoplastics from lactic acid
PH31064A (en) * 1990-09-07 1998-02-05 Nycomed As Of Nycoveten Polymers containing diester units.
ZA918168B (en) * 1990-10-16 1993-04-14 Takeda Chemical Industries Ltd Prolonged release preparation and polymers thereof.
IT1249045B (it) * 1991-02-21 1995-02-11 Himont Inc Processo per la sintesi allo stato solido di polimeri dell'acido lattico e prodotti cosi ottenuti
CH683149A5 (fr) * 1991-07-22 1994-01-31 Debio Rech Pharma Sa Procédé pour la préparation de microsphères en matériau polymère biodégradable.
US6326458B1 (en) 1992-01-24 2001-12-04 Cargill, Inc. Continuous process for the manufacture of lactide and lactide polymers
US5247059A (en) * 1992-01-24 1993-09-21 Cargill, Incorporated Continuous process for the manufacture of a purified lactide from esters of lactic acid
US5247058A (en) * 1992-01-24 1993-09-21 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US6005067A (en) 1992-01-24 1999-12-21 Cargill Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5142023A (en) * 1992-01-24 1992-08-25 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
US5258488A (en) * 1992-01-24 1993-11-02 Cargill, Incorporated Continuous process for manufacture of lactide polymers with controlled optical purity
FR2692147B1 (fr) * 1992-06-15 1995-02-24 Centre Nat Rech Scient Microsphères en polymère biorésorbable exemptes de tensioactif, leur préparation et leur application comme médicament.
ATE173520T1 (de) * 1992-10-02 1998-12-15 Cargill Inc Papier mit einer beschichtung aus schmelzstabilem polymer und dessen verfahren zur herstellung
US6005068A (en) 1992-10-02 1999-12-21 Cargill Incorporated Melt-stable amorphous lactide polymer film and process for manufacture thereof
AU5294893A (en) * 1992-10-02 1994-04-26 Cargill Incorporated A melt-stable lactide polymer fabric and process for manufacture thereof
US5338822A (en) * 1992-10-02 1994-08-16 Cargill, Incorporated Melt-stable lactide polymer composition and process for manufacture thereof
TW333456B (en) 1992-12-07 1998-06-11 Takeda Pharm Ind Co Ltd A pharmaceutical composition of sustained-release preparation the invention relates to a pharmaceutical composition of sustained-release preparation which comprises a physiologically active peptide.
US6090925A (en) 1993-03-09 2000-07-18 Epic Therapeutics, Inc. Macromolecular microparticles and methods of production and use
US6080429A (en) * 1993-10-25 2000-06-27 Genentech, Inc. Method for drying microspheres
US5643605A (en) * 1993-10-25 1997-07-01 Genentech, Inc. Methods and compositions for microencapsulation of adjuvants
US6913767B1 (en) 1993-10-25 2005-07-05 Genentech, Inc. Compositions for microencapsulation of antigens for use as vaccines
US5626862A (en) 1994-08-02 1997-05-06 Massachusetts Institute Of Technology Controlled local delivery of chemotherapeutic agents for treating solid tumors
TW448055B (en) * 1995-09-04 2001-08-01 Takeda Chemical Industries Ltd Method of production of sustained-release preparation
US5942253A (en) * 1995-10-12 1999-08-24 Immunex Corporation Prolonged release of GM-CSF
SE505146C2 (sv) * 1995-10-19 1997-06-30 Biogram Ab Partiklar för fördröjd frisättning
DE19545257A1 (de) 1995-11-24 1997-06-19 Schering Ag Verfahren zur Herstellung von morphologisch einheitlichen Mikrokapseln sowie nach diesem Verfahren hergestellte Mikrokapseln
AU4239597A (en) 1996-08-29 1998-03-19 Advanced Research And Technology Institute, Inc. Novel pharmacotherapeutic process and composition for central nervous system disorders
US5968895A (en) * 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20070185032A1 (en) * 1996-12-11 2007-08-09 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US6126919A (en) 1997-02-07 2000-10-03 3M Innovative Properties Company Biocompatible compounds for pharmaceutical drug delivery systems
US5989463A (en) * 1997-09-24 1999-11-23 Alkermes Controlled Therapeutics, Inc. Methods for fabricating polymer-based controlled release devices
US6217844B1 (en) * 1998-04-27 2001-04-17 Praecis Pharmaceuticals, Inc. Methods for detecting lesions in dense breast tissue using LHRH antagonists
US6565874B1 (en) * 1998-10-28 2003-05-20 Atrix Laboratories Polymeric delivery formulations of leuprolide with improved efficacy
US6458387B1 (en) * 1999-10-18 2002-10-01 Epic Therapeutics, Inc. Sustained release microspheres
ES2169980B1 (es) 1999-12-17 2003-11-01 Lipotec Sa Microcapsulas para la liberacion prolongada de farmacos.
TW200800298A (en) 2000-01-27 2008-01-01 Zentaris Ag Compressed microparticles for dry injection
WO2001080830A2 (en) * 2000-04-21 2001-11-01 Advanced Research And Technology Institute, Inc. Pharmacotherapeutic process and composition for central nervous system disorders
DE60118575T3 (de) * 2000-08-07 2011-05-19 Takeda Pharmaceutical Co. Ltd. Milchsäurepolymer und verfahren zu dessen herstellung
US6362308B1 (en) * 2000-08-10 2002-03-26 Alkermes Controlled Therapeutics Inc. Ii Acid end group poly(d,l-lactide-co-glycolide) copolymers high glycolide content
EP1335661B1 (de) 2000-10-27 2009-05-06 Baxter Healthcare S.A. Herstellung von mikrokügelchen
US8470359B2 (en) 2000-11-13 2013-06-25 Qlt Usa, Inc. Sustained release polymer
WO2002049620A2 (en) 2000-12-21 2002-06-27 Inhale Therapeutic Systems, Inc. Induced phase transition method for the production of microparticles containing hydrophobic active agents
EP1408876A4 (de) * 2001-06-22 2004-09-22 Durect Corp Koaxiale implantate nullter ordnung mit verlängerter freisetzung
TWI225416B (en) 2001-06-29 2004-12-21 Takeda Chemical Industries Ltd Sustained-release composition and process for producing the same
TWI332407B (en) * 2001-06-29 2010-11-01 Takeda Chemical Industries Ltd Controlled release composition and method of producting the same
JP4612239B2 (ja) * 2001-07-18 2011-01-12 三井化学株式会社 生体吸収性ポリヒドロキシカルボン酸の製造方法
US20050233945A1 (en) * 2003-07-18 2005-10-20 Larry Brown Methods for fabrication, uses and compositions of small spherical particles of insulin prepared by controlled phase separation
US20080026068A1 (en) * 2001-08-16 2008-01-31 Baxter Healthcare S.A. Pulmonary delivery of spherical insulin microparticles
WO2003015750A1 (en) * 2001-08-16 2003-02-27 Baxter International, Inc. Propellant-based microparticle formulations
JP2003192773A (ja) 2001-12-26 2003-07-09 Mitsui Chemicals Inc 生体吸収性ポリヒドロキシカルボン酸及びその製造法
US6849600B2 (en) * 2002-03-25 2005-02-01 The Regents Of The University Of California, Berkeley Corticotropin-releasing hormone analogs
US20050112087A1 (en) * 2003-04-29 2005-05-26 Musso Gary F. Pharmaceutical formulations for sustained drug delivery
US20060193825A1 (en) * 2003-04-29 2006-08-31 Praecis Phamaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
US20050142205A1 (en) * 2003-07-18 2005-06-30 Julia Rashba-Step Methods for encapsulating small spherical particles prepared by controlled phase separation
US20070092452A1 (en) * 2003-07-18 2007-04-26 Julia Rashba-Step Methods for fabrication, uses, compositions of inhalable spherical particles
JP2007508240A (ja) * 2003-07-22 2007-04-05 バクスター・インターナショナル・インコーポレイテッド 低分子量有機分子の小球状粒子ならびにその調製方法および使用方法
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
TW200529890A (en) * 2004-02-10 2005-09-16 Takeda Pharmaceutical Sustained-release preparations
JP4403846B2 (ja) * 2004-03-22 2010-01-27 東レ株式会社 ポリ乳酸のラクチド除去法
JP4403845B2 (ja) * 2004-03-22 2010-01-27 東レ株式会社 ラクチド含有量が少ないポリ乳酸の製造方法
EP1753404A1 (de) * 2004-05-12 2007-02-21 Baxter International Inc. Mikrokügelchen mit protein; die bei hohen konzentrationen des mittels injizierbar sind
US7815826B2 (en) * 2004-05-12 2010-10-19 Massachusetts Institute Of Technology Manufacturing process, such as three-dimensional printing, including solvent vapor filming and the like
JP2007537284A (ja) 2004-05-12 2007-12-20 バクスター インターナショナル インコーポレイテッド 核酸マイクロスフェア、その生成および送達
AU2005244851B2 (en) * 2004-05-12 2010-08-26 Baxter Healthcare S.A. Oligonucleotide-containing microspheres, their use for the manufacture of a medicament for treating diabetes type 1
US8728525B2 (en) * 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
TW200613012A (en) * 2004-07-02 2006-05-01 Takeda Pharmaceuticals Co Sustained-release composition, process for producing the same and use of the same
MX2007001760A (es) 2004-08-12 2007-07-24 Quest Pharmaceutical Services Composiciones farmaceuticas para la distribucion de liberacion controlada de compuestos biologicamente activos.
US20070254314A1 (en) * 2004-09-16 2007-11-01 Geier Mark R Methods of treating autism and autism spectrum disorders
US20080038316A1 (en) * 2004-10-01 2008-02-14 Wong Vernon G Conveniently implantable sustained release drug compositions
US8541413B2 (en) * 2004-10-01 2013-09-24 Ramscor, Inc. Sustained release eye drop formulations
WO2006039336A2 (en) * 2004-10-01 2006-04-13 Ramscor, Inc. Conveniently implantable sustained release drug compositions
US9993558B2 (en) 2004-10-01 2018-06-12 Ramscor, Inc. Sustained release eye drop formulations
US8394410B2 (en) * 2005-01-20 2013-03-12 Massachusetts Institute Of Technology Soft polylactides
CN101188996B (zh) * 2005-04-27 2013-03-27 巴克斯特国际公司 表面改性的微粒及其形成和使用方法
DE602006000381T2 (de) * 2005-04-28 2008-12-18 Nipro Corp., Osaka Bioabsorbierbare pharmazeutische Zusammensetzung enthaltend einen PLGA-Copolymer
US8840876B2 (en) * 2005-05-19 2014-09-23 Ethicon, Inc. Antimicrobial polymer compositions and the use thereof
US8882747B2 (en) * 2005-11-09 2014-11-11 The Invention Science Fund I, Llc Substance delivery system
JP2009520693A (ja) * 2005-12-08 2009-05-28 エムディーアールエヌエー，インコーポレイテッド 安定化されたエキセンディン製剤の粘膜送達
US20070154546A1 (en) * 2005-12-30 2007-07-05 Zhang Jack Y Sustained release pharmaceutical compositions
US20070196416A1 (en) 2006-01-18 2007-08-23 Quest Pharmaceutical Services Pharmaceutical compositions with enhanced stability
JP2009525372A (ja) * 2006-01-31 2009-07-09 ピュラック バイオケム ビー．ブイ． 残留モノマーから吸収性ポリマーを精製する方法
US20070179276A1 (en) * 2006-01-31 2007-08-02 Purac Biochem Bv Method for the purification of resorbable polymers from residual monomers
US20070281031A1 (en) * 2006-06-01 2007-12-06 Guohan Yang Microparticles and methods for production thereof
KR20140109509A (ko) 2006-07-11 2014-09-15 큐피에스 엘엘씨 펩타이드의 지속 방출 전달을 위한 의약 조성물
EP2056883B1 (de) 2006-08-04 2021-09-22 Baxter International Inc. Zusammensetzung auf mikrokügelchenbasis zur vorbeugung und/oder abwendung einer neuerkrankung an autoimmunem diabetes
MX2009003661A (es) * 2006-10-06 2009-04-22 Baxter Int Microcapsulas que contienen microparticulas modificadas en la superficie y metodos para formar y utilizar las mismas.
US8076448B2 (en) 2006-10-11 2011-12-13 Tolmar Therapeutics, Inc. Preparation of biodegradable polyesters with low-burst properties by supercritical fluid extraction
DK3276349T3 (da) 2006-11-01 2019-10-28 Ventana Med Syst Inc Haptener, haptenkonjugater, sammensætninger deraf og fremgangsmåder til fremstilling og anvendelse deraf
GEP20125597B (en) * 2006-12-18 2012-08-10 Takeda Pharmaceutical Sustained-release composition and production method thereof
SI3202814T1 (sl) 2007-02-15 2019-12-31 Tolmar Therapeutics, Inc. Poli-(laktid/glikolid) z nizkim razpokom in postopki za proizvodnjo polimerov
US8323615B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US20100047292A1 (en) * 2008-08-20 2010-02-25 Baxter International Inc. Methods of processing microparticles and compositions produced thereby
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
US8367427B2 (en) * 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
EP2358684B8 (de) 2008-10-20 2014-10-22 The Government of the United States of America as represented by the Secretary of the Department of Health and Human Services Schilddrüsen-stimulierende hormon (tsh) rezeptor agonisten mit eringem molekulargewicht
EP2364082A4 (de) 2008-10-21 2012-06-06 Oregon Health And Sciences University Naphthamide als antikrebsmittel
WO2010111238A2 (en) * 2009-03-23 2010-09-30 Micell Technologies, Inc. Improved biodegradable polymers
EP2246063A1 (de) 2009-04-29 2010-11-03 Ipsen Pharma S.A.S. GnRH Analoge enthaltende Retardformulierungen
WO2011005939A2 (en) 2009-07-09 2011-01-13 Mayo Foundation For Medical Education And Research Long acting atrial natriuretic peptide (la-anp) and methods for use thereof
US9365612B2 (en) 2010-01-29 2016-06-14 United States Of America As Represented By The Secretary, Department Of Health And Human Services Caspase inhibitors
EP2563777A4 (de) 2010-04-08 2013-09-04 Us Health Inverse agonisten und neutrale agonisten für den tsh-rezeptor
WO2012125486A1 (en) 2011-03-11 2012-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination chemotherapy for treating cancer
US9446048B2 (en) 2011-03-17 2016-09-20 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods for treating leukemia and disorders mediated by CBFβ and RUNX1 proteins
EP2751136B1 (de) 2011-08-30 2017-10-18 Mayo Foundation For Medical Education And Research Natriuretische polypeptide
US20140348865A1 (en) 2011-09-12 2014-11-27 The United States Of America, As Represented By The Secretary, Department Of Health And Human Ser. Immunogens based on an hiv-1 v1v2 site-of-vulnerability
US20140234360A1 (en) 2011-09-30 2014-08-21 The United States of America, as represented by the Secretary, Dept.of Health and Human Services Influenza vaccine
WO2013103896A1 (en) 2012-01-06 2013-07-11 Mayo Foundation For Medical Education And Research Treating cardiovascular or renal diseases
US9249103B2 (en) 2012-01-13 2016-02-02 Oregon Health & Science University Compounds, compositions and associated methods comprising 3-aryl quinolines
EP2858975B1 (de) 2012-06-08 2019-04-24 University of Pittsburgh - Of the Commonwealth System of Higher Education Fbxo3-inhibitoren
JP6272626B2 (ja) 2012-11-13 2018-01-31 ザ ユナイテッド ステイツ オブ アメリカ， アズ リプレゼンテッド バイ ザ セクレタリー， デパートメント オブ ヘルス アンド ヒューマン サービシーズ カンナビノイド受容体媒介性化合物
US9775895B2 (en) 2012-12-12 2017-10-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services HIV therapeutics and methods of making and using same
EP2996691A1 (de) 2013-05-16 2016-03-23 The U.S.A. as represented by the Secretary, Department of Health and Human Services Verbindungen zur hemmung medikamentenresistenter stämme der hiv-1-integrase
CN103300120B (zh) * 2013-06-25 2015-04-22 南京工业大学 一种绿色家禽家畜脱毛剂及其制备方法
US10882834B2 (en) 2013-09-20 2021-01-05 University of Pittsburgh—of the Commonwealth System of Higher Education Compounds for treating prostate cancer
US10398772B2 (en) 2014-01-08 2019-09-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Ras pathways as markers of protection against HIV and methods to improve vaccine efficacy
CN106660968B (zh) 2014-05-09 2020-02-07 美国政府(由卫生和人类服务部的部长所代表) 吡唑衍生物及其作为大麻素受体介体的用途
WO2016033100A1 (en) 2014-08-25 2016-03-03 Salk Institute For Biological Studies Novel ulk1 inhibitors and methods using same
EP3189067B1 (de) 2014-09-04 2021-05-19 The United States of America, as represented by The Secretary, Department of Health and Human Services Rekombinante hiv-1 hüllproteine und deren verwendung
WO2016064716A1 (en) 2014-10-20 2016-04-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Combination therapy of tshr antagonist and igfr inhibitor
EP3236998A1 (de) 2014-12-24 2017-11-01 The U.S.A. as represented by the Secretary, Department of Health and Human Services Rekombinante metapneumovirusproteine und deren verwendung
WO2016112036A1 (en) 2015-01-05 2016-07-14 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Myc g-quadruplex stabilizing small molecules and their use
CA2976922A1 (en) 2015-02-20 2016-08-25 Oregon Health & Science University Derivatives of sobetirome
EP3303325A1 (de) 2015-06-04 2018-04-11 The U.S.A. as represented by the Secretary, Department of Health and Human Services Cannabinoid-rezeptorvermittelnde verbindungen
WO2017044803A1 (en) 2015-09-09 2017-03-16 The United States Of America, As Represented By The Secretary Department Of Health And Human Service Expression vector delivery system and use thereof for inducing an immune response
WO2017151802A1 (en) 2016-03-04 2017-09-08 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor mediating compounds
LT3457851T (lt) 2016-05-18 2021-10-11 Oregon Health & Science University Sobetiromo dariniai
EP3471828A1 (de) 2016-06-16 2019-04-24 Acies Bio d.o.o. Zusammensetzungen und verfahren zur behandlung von krankheiten, die durch eine unzureichende pantothenatkinaseaktivität gekennzeichnet sind
TWI648291B (zh) * 2016-10-13 2019-01-21 傑安生技股份有限公司 氧化性修飾改善細胞穿透性胜肽之成藥性以作為藥物載體
EP3538131A4 (de) 2016-11-09 2020-07-01 Mayo Foundation for Medical Education and Research Manp-analoga
CA3043790A1 (en) 2016-12-16 2018-06-21 Institute For Research In Biomedicine Novel recombinant prefusion rsv f proteins and uses thereof
WO2019118803A1 (en) 2017-12-14 2019-06-20 The United States Of America, As Represented By The Secretary,Department Of Health And Human Services Chemical entities for lytic activation of kshv and therapeutic targeting of viral enzymes/proteins
AU2019243561A1 (en) 2018-03-29 2020-09-24 Elex Biotech, Inc. Compounds for treatment of cardiac arrhythmias and heart failure
CA3110224A1 (en) 2018-09-25 2020-04-02 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services 2'-halogenated-4'-thio-2'-deoxy-5-azacytidine analogs and use thereof
JP2022513449A (ja) 2018-12-12 2022-02-08 オートバーン セラピューティクス，インク． 新規な甲状腺模倣物
CN113784950A (zh) 2019-03-01 2021-12-10 速通医疗公司 新型拟甲状腺素药
WO2020185695A1 (en) 2019-03-11 2020-09-17 Oregon State University Analogues and derivatives of cephalotaxine and methods for making and using the compounds
US20210196648A1 (en) * 2019-12-31 2021-07-01 Industrial Technology Research Institute Drug-containing multilayer film and method for forming the same
CN112409765A (zh) * 2020-11-16 2021-02-26 深圳市正旺环保新材料有限公司 一种可降解环保塑料袋及其制备方法
CA3222837A1 (en) 2021-06-09 2022-12-15 John S. Schneekloth Compounds that bind non-canonical g-quadruplex structures and methods of making and using the same
GB2613656A (en) * 2021-12-13 2023-06-14 Pharmathen Sa Sustained release injectable pharmaceutical formulation of levothyroxine and process for preparation thereof
WO2023059867A1 (en) 2021-10-08 2023-04-13 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Compounds for treating or preventing alzheimer's disease
WO2023146771A1 (en) 2022-01-25 2023-08-03 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Gingerenone a prodrugs as senotherapeutics and methods of use
WO2023177568A1 (en) 2022-03-14 2023-09-21 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Cannabinoid receptor modulating compounds

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3297033A (en) * 1963-10-31 1967-01-10 American Cyanamid Co Surgical sutures
US3565869A (en) * 1968-12-23 1971-02-23 American Cyanamid Co Extrudable and stretchable polyglycolic acid and process for preparing same
US3755558A (en) * 1971-02-23 1973-08-28 Du Pont Polylactide drug mixtures for topical application atelet aggregation
US3839297A (en) * 1971-11-22 1974-10-01 Ethicon Inc Use of stannous octoate catalyst in the manufacture of l(-)lactide-glycolide copolymer sutures
US3912692A (en) * 1973-05-03 1975-10-14 American Cyanamid Co Process for polymerizing a substantially pure glycolide composition
US3890283A (en) * 1973-06-04 1975-06-17 American Cyanamid Co Process for post-polymerizing polyglycolic acid
US4249531A (en) * 1979-07-05 1981-02-10 Alza Corporation Bioerodible system for delivering drug manufactured from poly(carboxylic acid)
US4273920A (en) * 1979-09-12 1981-06-16 Eli Lilly And Company Polymerization process and product
PH19942A (en) * 1980-11-18 1986-08-14 Sintex Inc Microencapsulation of water soluble polypeptides
US4479911A (en) * 1982-01-28 1984-10-30 Sandoz, Inc. Process for preparation of microspheres and modification of release rate of core material
US4605730A (en) * 1982-10-01 1986-08-12 Ethicon, Inc. Surgical articles of copolymers of glycolide and ε-caprolactone and methods of producing the same
US4523591A (en) * 1982-10-22 1985-06-18 Kaplan Donald S Polymers for injection molding of absorbable surgical devices
CH656884A5 (de) * 1983-08-26 1986-07-31 Sandoz Ag Polyolester, deren herstellung und verwendung.
JPS60100516A (ja) * 1983-11-04 1985-06-04 Takeda Chem Ind Ltd 徐放型マイクロカプセルの製造法

Also Published As

Publication number Publication date
HUT43488A (en) 1987-11-30
CA1262005A (en) 1989-09-26
EP0202065A2 (de) 1986-11-20
DE3688213T2 (de) 1993-09-23
JP2660401B2 (ja) 1997-10-08
JPS6254760A (ja) 1987-03-10
JPH08169818A (ja) 1996-07-02
HU196703B (en) 1989-01-30
US4849228A (en) 1989-07-18
EP0202065A3 (en) 1987-10-21
US4728721A (en) 1988-03-01
EP0202065B1 (de) 1993-04-07
DE3688213D1 (de) 1993-05-13
HK5796A (en) 1996-01-19
JP2551756B2 (ja) 1996-11-06

Similar Documents

Publication Publication Date Title
ATE87946T1 (de) Polymer, seine herstellung und verwendung.
SE8501022D0 (sv) Format alster och forfarande for dess framstellning
DE3567470D1 (en) Copolymer and method for producing the same
DE3781177D1 (de) Gemischte phosphorsaeurediester, ihre herstellung und verwendung als entzuendungshemmende mittel.
SE8801240D0 (sv) Dosage form comprising parallel laminae
KR880700668A (ko) 특정 생체조직 부위로의 전달을 위한 아미노산 킬레이트의 조성물
DE59005250D1 (de) Neue Thienylcarbonsäureester von Aminoalkoholen, ihre Quaternierungsprodukte sowie die Herstellung und Verwendung dieser Verbindungen.
SE8603582D0 (sv) Komposition innehallande l-dopa
DE3688038T2 (de) Verwendung von buspiron zur herstellung von pharmazeutischen zusammensetzungen zur linderung von krankhaften angst.
ES2140565T3 (es) Nuevos derivados de pirazina-carboxamida, su preparacion y su utilizacion en medicamentos.
ES8701717A1 (es) Un procedimiento para la preparacion de nuevos derivados del acido (5-amino-2-hidroxi)benzoico.
ES8800605A1 (es) Procedimiento para preparar una composicion coloeada de utilidad en cirugia ocular.
ES2014060A6 (es) Procedimiento para la obtencion de productos farmaceuticos que actuan en particualr sobre el corazon y el sistema cardiovascular.
DK0610697T3 (da) Imidazolyl-substituerede phenyleddikesyreprolinamider.
ES2009569A6 (es) Procedimiento de preparacion de una composicion farmaceutica a base de algas que contengan selenio que actua sobre el corazon y el sistema cardiovascular.
EP0199257A3 (de) Ester von L-Aminodicarboxylsäure und eine geniessbare, sie als Süssstoff enthaltende Zusammensetzung
ES2087883T3 (es) Derivados de politetrahidrofurano con grupos aromaticos terminales.
RU93048332A (ru) Состав на основе гексадецилфосфохолина, способ его получения, лекарственное средство
ATE106407T1 (de) Derivate von thiazolidin-4-carbonsäure, deren herstellung und sie enthaltende pharmazeutische zusammensetzungen.
EP0367302A3 (de) Verfahren zur Halbsynthese von menschlichem Insulin, dabei zu verwendende, vernetzte, wasserlösliche Achromobacter Protease I und Verfahren zu dessen Herstellung
DK8503352A (de)
ES8608861A1 (es) Procedimiento para la preparacion de composiciones farmaceuticas hidrosolubles a base de sales de fosfomicina.
EP0192327A3 (de) Verwendung von Phosphonoameisensäure, ihre Ester und Salze zur Herstellungs eines Medicaments bei der Behandlung von AIDS
IT1247508B (it) Composizioni farmaceutiche contenenti l'estere 4-(2 metilamminoetil)- 1,2- fenilenicodell`acido 2-metilpropanoico per il trattamento della neurootticopatia glaucomatosa
YU47871B (sh) Derivati aminokiselina

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification
EELA Cancelled due to lapse of time